{"title":"天使翼式房间隔缺损闭合装置。","authors":"Das, Harrison, O'Laughlin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Angel Wings Das device (Microvena Corporation, White Bear Lake, MN) is a self-centering, nitinol-polyester prosthesis with two square-shaped disks and a customized delivery catheter. The implantation success rate for atrial septal defects (ASDs) was 92% and 94% in the Phase I and II trials in the United States, and 97% and 100% for patients with patent foramen ovale (PFO). Residual shunts in the Phase II United States trials at 24 hours by transthoracic echocardiography are as follows: For patients with ASDs, 86% have no or less than 1-mm shunts and 14% have 1- to 2-mm shunts. None of the patients had a large residual shunt. Patients with PFOs had no significant residual shunts at 24 hours. There were no device-related deaths, embolization after successful closure, or episodes of infective endocarditis. The device has been modified to have two circular disks. It is retrievable into the delivery catheter and repositionable. The Angel Wings II device is anticipated to enter clinical use in the near future.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"2 1","pages":"78-85"},"PeriodicalIF":0.0000,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Angel Wings Das Devices for Atrial Septal Defect Closure.\",\"authors\":\"Das, Harrison, O'Laughlin\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Angel Wings Das device (Microvena Corporation, White Bear Lake, MN) is a self-centering, nitinol-polyester prosthesis with two square-shaped disks and a customized delivery catheter. The implantation success rate for atrial septal defects (ASDs) was 92% and 94% in the Phase I and II trials in the United States, and 97% and 100% for patients with patent foramen ovale (PFO). Residual shunts in the Phase II United States trials at 24 hours by transthoracic echocardiography are as follows: For patients with ASDs, 86% have no or less than 1-mm shunts and 14% have 1- to 2-mm shunts. None of the patients had a large residual shunt. Patients with PFOs had no significant residual shunts at 24 hours. There were no device-related deaths, embolization after successful closure, or episodes of infective endocarditis. The device has been modified to have two circular disks. It is retrievable into the delivery catheter and repositionable. The Angel Wings II device is anticipated to enter clinical use in the near future.</p>\",\"PeriodicalId\":80270,\"journal\":{\"name\":\"Current interventional cardiology reports\",\"volume\":\"2 1\",\"pages\":\"78-85\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current interventional cardiology reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Angel Wings Das装置(Microvena Corporation, White Bear Lake, MN)是一种自定心镍钛醇-聚酯假体,带有两个方形圆盘和一个定制的输送导管。在美国的I期和II期试验中,房间隔缺损(ASDs)的植入成功率分别为92%和94%,卵圆孔未闭(PFO)患者的植入成功率分别为97%和100%。在美国II期临床试验中,24小时经胸超声心动图显示的剩余分流如下:对于asd患者,86%的患者没有或小于1毫米的分流,14%的患者有1至2毫米的分流。没有一个病人有很大的残余分流。PFOs患者在24小时内没有明显的残余分流。没有器械相关的死亡,成功闭合后的栓塞,或感染性心内膜炎发作。该设备已被修改为具有两个圆形磁盘。它是可收回到输送导管和可重新定位。天使之翼II装置预计将在不久的将来进入临床使用。
The Angel Wings Das Devices for Atrial Septal Defect Closure.
The Angel Wings Das device (Microvena Corporation, White Bear Lake, MN) is a self-centering, nitinol-polyester prosthesis with two square-shaped disks and a customized delivery catheter. The implantation success rate for atrial septal defects (ASDs) was 92% and 94% in the Phase I and II trials in the United States, and 97% and 100% for patients with patent foramen ovale (PFO). Residual shunts in the Phase II United States trials at 24 hours by transthoracic echocardiography are as follows: For patients with ASDs, 86% have no or less than 1-mm shunts and 14% have 1- to 2-mm shunts. None of the patients had a large residual shunt. Patients with PFOs had no significant residual shunts at 24 hours. There were no device-related deaths, embolization after successful closure, or episodes of infective endocarditis. The device has been modified to have two circular disks. It is retrievable into the delivery catheter and repositionable. The Angel Wings II device is anticipated to enter clinical use in the near future.